Citizens Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $149
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsPrice Target
Citizens analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the price target from $93 to $149.
Citizens analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the price target from $93 to $149.